Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Shares Issued (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Shares Issued for 12 consecutive years, with $165000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 31.54% to $165000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $406000.0 through Dec 2025, down 56.16% year-over-year, with the annual reading at $353000.0 for FY2025, 61.88% down from the prior year.
  • Shares Issued hit $165000.0 in Q4 2025 for Coherus Oncology, down from $241000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $36.6 million in Q2 2021 to a low of -$30.5 million in Q4 2021.
  • Historically, Shares Issued has averaged $1.0 million across 5 years, with a median of $241000.0 in 2024.
  • Biggest five-year swings in Shares Issued: skyrocketed 1728.41% in 2021 and later plummeted 5971.43% in 2024.
  • Year by year, Shares Issued stood at -$30.5 million in 2021, then soared by 102.18% to $665000.0 in 2022, then surged by 146.47% to $1.6 million in 2023, then crashed by 85.3% to $241000.0 in 2024, then tumbled by 31.54% to $165000.0 in 2025.
  • Business Quant data shows Shares Issued for CHRS at $165000.0 in Q4 2025, $241000.0 in Q4 2024, and -$822000.0 in Q2 2024.